Arvinas, Inc. (NASDAQ:ARVN) CAO David K. Loomis Sells 1,214 Shares

Arvinas, Inc. (NASDAQ:ARVN) CAO David K. Loomis sold 1,214 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.75, for a total transaction of $20,334.50. Following the transaction, the chief accounting officer now directly owns 18,863 shares in the company, valued at $315,955.25. The trade was a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Arvinas Trading Down 3.4 %

Arvinas stock opened at $17.08 on Thursday. The company has a market capitalization of $1.17 billion, a PE ratio of -6.16 and a beta of 1.88. The stock has a 50-day moving average price of $18.38 and a two-hundred day moving average price of $22.76. Arvinas, Inc. has a 12 month low of $16.07 and a 12 month high of $51.51.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm posted ($2.53) earnings per share. As a group, analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Institutional Trading of Arvinas

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in Arvinas during the 4th quarter worth $28,000. KBC Group NV increased its stake in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after buying an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Arvinas by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after acquiring an additional 440 shares during the last quarter. Quantbot Technologies LP lifted its stake in shares of Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after acquiring an additional 2,601 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new stake in Arvinas in the fourth quarter valued at approximately $171,000. Institutional investors own 95.19% of the company’s stock.

Wall Street Analyst Weigh In

ARVN has been the topic of several analyst reports. Stephens began coverage on shares of Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. Stifel Nicolaus dropped their price objective on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Oppenheimer boosted their target price on Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Barclays dropped their price target on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price objective (down previously from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $60.00.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.